**Supplementary Material**

**Suppl 1.** Co-expression of HER family members, EGFRvIII, CD44, and CD109 in stomach cancer tumor samples at different cut-off values

|  |  |
| --- | --- |
| **Markers** | **Number of positive tumors (%)** |
| **≥ 5% cut-off** | **≥ 10% cut-off** | **≥ 20% cut-off** | **≥ 50% cut- off** |
| **Wt-EGFR/HER2** | 7 (9.0) | 4 (5.1) | 1 (1.3) | 0 |
| Wt-EGFR/HER3 | 1 (1.3) | 0 | 0 | 0 |
| Wt-EGFR/HER4 | 3 (3.8) | 2 (2.6) | 0 | 0 |
| Wt-EGFR/EGFRvIII | 4 (5.1) | 1 (1.3) | 1 (1.3) | 0 |
| Wt-EGFR/CD44 | 4 (5.1) | 2 (2.6) | 1 91.3) | 0 |
| **Wt-EGFR/CD109** | 8 (10.3) | 6 (7.7) | 3 (3.8) | 1 (1.3) |
| Wt-EGFR/Claudin18.2 | 2 (2.6) | 1 (1.3) | 1 (1.3) | 0 |
| Wt-EGFR/HER2/HER4 | 1 (1.3) | 0 | 0 | 0 |
| Wt-EGFR/HER2/EGFRvIII | 3 (3.8) | 1 (1.3) | 1 (1.3) | 0 |
| Wt-EGFR/HER2/CD44 | 2 (2.6) | 1 (1.3) | 1 (1.3) | 0 |
| Wt-EGFR/HER2/CD109 | 4 (5.1) | 3 (3.8) | 1 (1.3) | 1 (1.3) |
| Wt-EGFR/HER2/Claudin18.2 | 1(1.3) | 0 | 0 | 0 |
| Wt-EGFR/HER2/HER3/CD109 | 1 (1.3) | 0 | 0 | 0 |
| Wt-EGFR/HER3/CD109 | 1 (1.3) | 0 | 0 | 0 |
| Wt-EGFR/HER4/EGFRvIII | 3 (3.8) | 0 | 0 | 0 |
| Wt-EGFR/HER4/CD44 | 2 (2.6) | 1 (1.3) | 0 | 0 |
| Wt-EGFR/HER4/CD109 | 2 (2.6) | 2 (2.6) | 0 | 0 |
| Wt-EGFR/HER4/Claudin18.2 | 1 (1.3) | 0 | 0 | 0 |
| Wt-EGFR/EGFRvIII/CD44 | 2 (2.6) | 1 (1.3) | 1 (1.3) | 0 |
| Wt-EGFR/EGFRvIII/CD109 | 2 (2.6) | 0 | 0 | 0 |
| Wt-EGFR/EGFRvIII/Claudin 18.2 | 2 (2.6) | 0 | 0 | 0 |
| Wt-EGFR/CD44/CD109 | 4 (5.1) | 2 (2.6) | 1 (1.3) | 0 |
| Wt-EGFR/CD44/Claudin 18.2 | 2 (2.6) | 0 | 0 | 0 |
|  |
| HER2/HER3 | 6 (7.7) | 4 (5.1) | 2 (2.6) | 0 |
| **HER2/HER4** | 21 (26.9) | 14 (17.9) | 11 (14.1) | 1 (1.3) |
| **HER2/EGFRvIII** | 22 (28.2) | 12 (15.4) | 4 (5.1) | 0 |
| **HER2/CD44** | 26 (33.3) | 21 (26.9) | 16 (20.5) | 4 (5.1) |
| **HER2/CD109** | 38 (48.7) | 34 (43.6) | 24 (30.8) | 10 (12.8) |
| **HER2/Claudin 18.2** | 25 (32.1) | 19 (24.4) | 13 (16.7) | 4 (5.1) |
| HER2/HER3/HER4 | 1 (1.3) | 1 (1.3) | 1 (1.3) | 0 |
| HER2/HER3/EGFRvIII | 2 (2.6) | 1 (1.3) | 0 | 0 |
| HER2/HER3/CD44 | 2 (2.6) | 0 | 0 | 0 |
| HER2/HER3/CD109 | 5 (6.4) | 3 (3.8) | 2 (2.6) | 0 |
| HER2/HER3/Claudin 18.2 | 1 (1.3) | 0 | 0 | 0 |
| HER2/HER3/HER4/CD109 | 1 (1.3) | 1 (1.3) | 1 (1.3) | 0 |
| HER2/HER4/EGFRvIII | 6 (7.7) | 1 (1.3) | 0 | 0 |
| HER2/HER4/EGFRVIII/CD44 | 3 (3.8) | 0 | 0 | 0 |
| **HER2/EGFRvIII/CD44** | 9 (11.5) | 4 (5.1) | 4 (5.1) | 0 |
| **HER2/EGFRvIII/CD109** | 13 (16.7) | 5 (6.4) | 1 (1.3) | 0 |
| HER2/EGFRvIII/Claudin 18.2 | 6 (7.7) | 1 (1.3) | 0 | 0 |
| **HER2/CD44/CD109** | 20 (25.6) | 16 (20.5) | 10 (12.8) | 3 (3.8) |
| **HER2/CD44/Claudin 18.2** | 13 (16.7) | 9 (11.5) | 3 (3.8) | 0 |
| **HER2/CD44/CD109/Claudin 18.2** | 12 (15.4) | 9 (11.5) | 2 (2.6) | 0 |
| **HER2/ CD109/Claudin 18.2** | 20 (25.6) | 16 (20.5) | 9 (11.5) | 2 (2.6) |
|  |
| HER3/HER4 | 1 (1.3) | 1 (1.3) | 1 (1.3) | 0 |
| HER3/EGFRvIII | 3 (3.8) | 1 (1.3) | 0 | 0 |
| HER3/CD44 | 2 (2.6) | 0 | 0 | 0 |
| HER3/CD109 | 5 (6.4) | 3 (3.8) | 2 (2.6) | 0 |
| HER3/Claudin 18.2 | 2 (2.6) | 0 | 0 | 0 |
| HER3/HER4/CD109 | 1 (1.3) | 1 (1.3) | 1 (1.3) | 0 |
| HER3/EGFRvIII/CD44 | 1 (1.3) | 0 | 0 | 0 |
| HER3/EGFRvIII/Claudin 18.2 | 1 (1.3) | 0 | 0 | 0 |
| HER3/CD44/CD109 | 2 (2.6) | 0 | 0 | 0 |
| HER3/CD44/Claudin 18.2 | 1 (1.3) | 0 | 0 | 0 |
| HER3/CD109/Claudin 18.2 | 1 (1.3) | 0 | 0 | 0 |
| HER3/CD44/CD109/Claudin 18.2 | 1 (1.3) | 0 | 0 | 0 |
|  |
| **HER4/EGFRvIII** | 7 (9.0) | 1 (1.3) | 0 | 0 |
| **HER4/CD44** | 15 (19.2) | 8 (10.3) | 7 (9.0) | 0 |
| **HER4/CD109** | 19 (24.4) | 16 (20.5) | 8 (10.3) | 1 (1.3) |
| **HER4/Claudin 18.2** | 13 (16.7) | 8 (10.3) | 4 (5.1) | 0 |
| HER4/EGFRvIII/CD44 | 4 (5.1) | 0 | 0 | 0 |
| HER4/EGFRvIII/CD109 | 3 (3.8) | 0 | 0 | 0 |
| HER4/EGFRvIII/Claudin 18.2 | 2 (2.6) | 0 | 0 | 0 |
| **HER4/CD44/CD109** | 11 (14.1) | 7 (9.0) | 5 (6.4) | 0 |
| **HER4/CD44/Claudin 18.2** | 8 (10.3) | 3 (3.8) | 0 | 0 |
| **HER4/CD109/Claudin 18.2** | 13 (16.7) | 8 (10.3) | 3 (3.8) | 0 |
| **HER4/CD44/CD109/Claudin 18.2** | 8 (10.3) | 3 (3.6) | 0 | 0 |
|  |
| **EGFRvIII/CD44** | 10 (12.8) | 4 (5.1) | 4 (5.1) | 1 1.3) |
| **EGFRvIII/CD109** | 14 (17.9) | 6 (7.7) | 2 (2.6) | 0 |
| **EGFRvIII/Claudin 18.2** | 10 (12.8) | 2 (2.6) | 0 | 0 |
| **EGFRvIII/CD44/CD109** | 8 (10.3) | 3 (3.8) | 1 (1.3) | 0 |
| EGFRvIII/CD44/Claudin 18.2 | 4 (5.1) | 0 | 0 | 0 |
| **EGFRvIII/CD109/Claudin 18.2** | 7 (9.0) | 2 (2.6) | 0 | 0 |
| EGFRvIII/CD44/CD109/Claudin 18.2 | 3 (3.8) | 0 | 0 | 0 |
|  |
| **CD44/CD109** | 24 (30.8) | 20 (25.6) | 13 (16.7) | 5 (6.4) |
| **CD44/Claudin 18.2** | 15 (19.2) | 11 (14.1) | 3 (3.8) | 2 (2.6) |
| **CD44/CD109/Claudin 18.2** | 14 (17.9) | 10 (12.8) | 2 (2.6) | 1 91.3) |
|  |
| **CD109/Claudin 18.2** | 25 (32.1) | 21 (26.0) | 12 (15.4) | 1. (6.4)
 |